In vitro activity of loracarbef against TEM extended-spectrum beta-lactamase-producing Escherichia coli strains and its interaction with the enzymes.
The in vitro activity of loracarbef was evaluated against Escherichia coli strains producing TEM extended-spectrum beta-lactamases (ESBLs). The MICs of loracarbef were lower than those of cefaclor and cephalothin. The antibiotic was active (MICs < or = 2 mg/l) against strains producing TEM-6, TEM-8, TEM-10, TEM-16, TEM-26 and TEM-28 beta-lactamases. The MICs for TEM-3-, TEM-5- and TEM-24-producing strains were higher (> or = 16 mg/l). Hydrolysis studies indicated that the latter beta-lactamases inactivated loracarbef more efficiently than the remaining TEM-type ESBLs examined.
Department of Bacteriology, Hellenic Pasteur Institute, Athens, Greece.
E E
EE
Prinarakis
L S
LS
Tzouvelekis
N J
NJ
Legakis
D002511:Cephalosporins / Q000378:metabolism / Q000494:pharmacology*; D004355:Drug Stability; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology; D006868:Hydrolysis; D008826:Microbial Sensitivity Tests; D010957:Plasmids / Q000235:genetics; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000737:chemistry / Q000378:metabolism*
D002511:Cephalosporins; C054920:loracarbef; D001618:beta-Lactamases